TargetBeta
MET
MET proto-oncogene, receptor tyrosine kinase · also HGFR, RCCP2, DFNB97 · IPT domain containing
25 programs in company-led studies act on MET, from 18 companies: 9 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 3610 running | KDR | ChEMBL |
| Crizotinibrule | Pfizer | phase 4 | 312 running | ALK, EML4, MST1R, NPM1, ROS1 | NCIt |
| telisotuzumab adizutecan | AbbVie | phase 3 | 1818 running | – | the company's pipeline |
| zanzalintinibrule | Exelixis | phase 3 | 1715 running | AXL, KDR | NCIt |
| amivantamabrule | Johnson & Johnson | phase 3 | 1613 running | EGFR | NCIt |
| vebreltinibrule | Beijing Pearl Biotechnology Limited Liability | phase 3 | 94 running | – | NCIt |
| glumetinibrule | Haihe Biopharma | phase 3 | 84 running | – | NCIt |
| bafisontamabrule | Shanghai EpimAb Biotherapeutics | phase 3 | 54 running | EGFR | NCIt |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 33 running | EGFR | the company's pipeline |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 82 running | AXL | the company's pipeline |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 72 running | – | a judged reading |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 77 running | – | the company's pipeline |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 55 running | EGFR | the company's pipeline |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 54 running | EGFR | NCIt |
| c-Met Inhibitor ANS014004rule | Avistone Biotechnology | phase 2 | 33 running | – | NCIt |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 33 running | EGFR | the company's pipeline |
| Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703rule | Chong Kun Dang Pharmaceutical | phase 2 | 11 running | – | NCIt |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 11 running | EGFR | NCIt |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | Tavotek Biotherapeutics | phase 1 | 22 running | EGFR, VEGFA | NCIt |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 22 running | EGFR | the company's pipeline |
| ABBV-253 | AbbVie | phase 1 | 11 running | – | the company's pipeline |
| Anti-c-Met Antibody-drug Conjugate YL211 | MediLink Therapeutics (Suzhou) | phase 1 | 11 running | – | the company's pipeline |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 11 running | EGFR | a judged reading |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 11 running | EGFR | NCIt |
| HLX48 | Fosun Pharma | phase 1 | 11 running | EGFR | the company's pipeline |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 15 programs
- Neoplasms, 7 programs
- Colorectal Neoplasms, 5 programs
- Carcinoma, Hepatocellular, 3 programs
- Carcinoma, Renal Cell, 2 programs
- Glioblastoma, 2 programs
- Lung Neoplasms, 2 programs
- Squamous Cell Carcinoma of Head and Neck, 2 programs
- Stomach Neoplasms, 2 programs
- Adenoma, Islet Cell, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026telisotuzumab adizutecan · AbbVie · phase 3 · NCT06107413
- Dec 2026SHR-1826 · Jiangsu HengRui Medicine · phase 2 · NCT06844474
- Dec 2026TQB2922 · Sino Biopharmaceutical · phase 2 · NCT06188624
- Dec 15, 2026zanzalintinib · Exelixis · phase 3 · NCT05678673
- Dec 25, 2026glumetinib · Haihe Biopharma · phase 3 · NCT06525350
- Dec 31, 2026amivantamab · Johnson & Johnson · phase 3 · NCT02609776
- Jan 2027vilzemetkib · Sino Biopharmaceutical · phase 3 · NCT06860971
- Feb 2027TQB6411 · Sino Biopharmaceutical · phase 2 · NCT07367516
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.